Supriya Lifescience vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Supriya Lifescience (SUPRIYA) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 18, 2026.
As of Aug 18, 2026, Fair Value Calculator sees Supriya Lifescience as the less overvalued of the two: Supriya Lifescience trades at ₹784 versus a fair value of ₹503 (-36%), while Vertex Pharmaceuticals trades at $516 versus $279 (-46%).
Supriya Lifescience
SUPRIYA.NSE · INR · Health Care
-36%
upside to fair value
overvalued
Price₹784
Fair Value₹503
Quality58/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-46%
upside to fair value
overvalued
Price$516
Fair Value$279
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Supriya LifescienceVertex Pharmaceuticals
Valuation
30.2×P/E (TTM)28.8×
9.52×P/S (TTM)10.06×
6.58×P/B6.59×
26.5×EV/EBITDA23.8×
—PEG1.72×
0.1%Dividend yield0.1%
₹1.00Dividend per share—
Profitability
25%Net margin36%
32%Operating margin38%
19%Return on equity24%
13%Return on assets12%
Growth
50%Revenue growth (YoY)8%
22.4%Avg. growth/yr (3Y)10.6%
16.5%Avg. growth/yr (5Y)14.2%
Balance & size
—Debt / equity0.03×
$827MMarket cap$123B
expensiveGrowth qualityhealthy
Supriya Lifescience leads: 7 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Supriya Lifescienceof which business quality 57 · market factors 57Vertex Pharmaceuticalsof which business quality 77 · market factors 72
ProfitabilityMargins and returns on capital today
71
72
Quality GrowthAre margins and returns improving?
43
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
7
58
Low VolatilityCalm price path (market factor)
60
86
MomentumPrice trend over the last 3–12 months (market factor)
59
59
52W MomentumDistance to the 52-week high (market factor)
49
79
Net IssuanceBuybacks instead of dilution
82
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Supriya Lifescience
DCF Models₹477
Earnings-Based₹503
Dividend Discount₹17.60
Multiples₹482
Asset-Based₹99.71
Growth DCF₹285
Economic Profit₹344
Growth Earnings₹710
25 of 26 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
19 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Supriya Lifescience
Bear ₹213Fair Value ₹503Bull ₹738
₹784 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$516 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Supriya Lifescience · Health Care
Quality score58 · above median
Fair value upside-36% · below median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-46% · below median
Bottom line
As of Aug 18, 2026, Fair Value Calculator sees Supriya Lifescience as the less overvalued of the two: Supriya Lifescience trades at ₹784 versus a fair value of ₹503 (-36%), while Vertex Pharmaceuticals trades at $516 versus $279 (-46%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
